Antibody therapeutic - China Biologic Products
Latest Information Update: 28 Feb 2024
At a glance
- Originator China Biologic Products
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunodeficiency disorders
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Immunodeficiency-disorders in China (IV)
- 09 Jan 2020 China Food and Drug Administration approved clinical trial application for Antibody therapeutic in immuno deficiency and auto-immune deficiency disorders (China Biologic Products pipeline, January 2020).
- 03 Jan 2020 Preclinical trials in Immunodeficiency disorders in China (Parenteral) (China Biologic Products pipeline)